XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies
Kruer, Traci L., Quintana, Ariel, Ferrall-Fairbanks, Meghan, Zhang, Ling, Newman, Hannah, McLemore, Amy F, Yang, Qin, Bencrentsil, Nana, Komrokji, Rami S., Chaudhry, Sana, Totiger, Tulasigeri M, Figueroa, Maria Ken E., Taylor, Justin, Sallman, David A., Padron, Eric
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article